MHC and MHC-like molecules: Structural perspectives on the design of molecular vaccines

Advances in Experimental Medicine and Biology

Volumn 640, Issue , 2008, Pages 252-267

  Apostolopoulos, Vasso ^a   Lazoura, Eliada ^b   Yu, Minmin ^b  

^a BURNET INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; PEPTIDE; PEPTIDE FRAGMENT; T LYMPHOCYTE RECEPTOR; VACCINE; HISTOCOMPATIBILITY ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT VACCINE;

ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELL SURFACE; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; VACCINES, SYNTHETIC;

EID: 58149341301     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-09789-3_19     Document Type: Review

References (78)

1. Kindred B, Shreffler DC. H-2 dependence of co-operation between T and B cells in vivo. J Immunol 1972; 109:940-3.
2. Rosenthal AS, Shevach EM. Function of macrophages in antigen recognition by guinea pig T-lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J Exp Med 1973; 138:1194-212.
3. Zinkernagel RM, Doherty PC. Restriction of in vitro T-ceil-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248:701-2.
4. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994; 153:4925-33.
5. Zwickey HL, Potter TA. Antigen secreted from noncytosolic Listeria monocytogenes is processed by the classical MHC class I processing pathway. J Immunol 1999; 162:6341-50.
6. Bjorkman PJ, Saper MA, Samraoui B et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329:506-12.
7. Apostoiopoulos V, Lazoura E. Noncanonical peptides in complex with MHC class I. Expert Rev Vaccines 2004; 3:151-62.
8. Apostoiopoulos V, McKenzie IF, Wilson lA. Getting into the groove: Unusual features of peptide binding to MHC class I molecules and implications in vaccine design. Front Biosci 2001; 6:D1311-20.
9. Apostoiopoulos V, Yu M, McKenzie IF et al. Structural impUcations for the design of molecular vaccines. Curr Opin Mol Ther 2000; 2:29-36.
10. Lazoura E, Apostolopoulos V. Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem 2005; 12:1481-94.
11. Lazoura E, Apostolopoulos V. Rational Peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 2005; 12:629-39.
12. Pietersz GA, Pouniotis DS, Apostolopoulos V. Design of peptide-based vaccines for cancer. Curr Med Chem 2006; 13:1591-607.
13. Garrett TP, Saper MA, Bjorkman PJ et al. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989; 342:692-6.
14. Rammensee HG, Friede T, Stevanoviic S. MHC Hgands and peptide motifs: First listing. Immimogenetics 1995; 41:178-228.
15. Falk K, Rotzschke O, Stevanovic S et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351:290-6.
16. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995; 7:85-96.
17. Haurum JS, Hoier IB, Arsequell G et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 1999; 190:145-50.
18. Glithero A, Tormo J, Haurum JS et al. Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 1999; 10:63-74.
19. Speir JA, Abdel-Motal UM, Jondal M et al. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999; 10:51-61.
20. Apostolopoulos V, Yuriev E, Ramsland PA et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 2003; 100:15029-34.
21. Andersen MH, BonfiU JE, Neisig A et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules and recognized by phosphopeptide-specific CTL. J Immunol 1999; 163:3812-8.
22. Apostolopoulos V, Haurum JS, McKenzie IF. MUCl peptide epitopes associated with five difFerent H-2 class I molecules. Eur J Immunol 1997; 27:2579-87.
23. Apostolopoulos V, Karanikas V, Haurum JS et al. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 1997; 159:5211-8.
24. Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T-lymphocytes. Nature 1989; 337:651-3.
25. Horig H, Young AC, Papadopoulos NJ et al. Binding of longer peptides to the H-2Kb heterodimer is restricted to peptides extended at their C terminus: Refinement of the inherent MHC class I peptide binding criteria. J Immunol 1999; 163:4434-41.
26. Rudolph MG, Stevens J, Speir JA et al. Crystal structures of two rat MHC class la (RTl-A) molecules that are associated differentially with peptide transporter alleles TAP-A and TAP-B. J Mol Biol 2002; 324:975-90.
27. Speir JA, Stevens J, Joly E et al. Two difFerent, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RTl-Aa. Immunity 2001; 14:81-92.
28. Tynan FE, Burrows SR, Buckle AM et al. T-cell receptor recognition of a super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol 2005; 6:1114-22.
29. Miles JJ, Elhassen D, Borg NA et al. CTL recognition of a bulged viral peptide involves biased TCR selection. J Immunol 2005; 175:3826-34.
30. Tynan FE, Borg NA, Miles JJ et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005; 280:23900-9.
31. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol 2006; 27:11-6.
32. Samino Y, Lopez D, Guil S et al. A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural ligands from HIV envelope protein. J Biol Chem 2006; 281:6358-65.
33. Collins EJ, Garboczi DN, Wiley DC. Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature 1994; 371:626-9.
34. Chen Y, Sidney J, Southwood S et al. Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in difFerent conformations. J Immunol 1994; 152:2874-81.
35. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a noncanonical low-affinity peptide complexed with MHC class I: A new approach for vaccine design. J Mol Biol 2002; 318:1293-305.
36. Eisen HN, Sykulev Y, Tsomides TJ. Antigen-specific T-cell receptors and their reactions with complexes formed by peptides with major histocompatibility complex proteins. Adv Protein Chem 1996; 49:1-56.
37. Gillanders WE, Hanson HL, Rubocki RJ et ai. Class I-restricted cytotoxic T-cell recognition of split peptide ligands. Int Immunol 1997; 9:81-9.
38. Glithero A, Tormo J, Doering K et al. The crystal structure of H-2D{b) complexed with a partial peptide epitope suggests a major histocompatibility complex class I assembly intermediate. J Biol Chem 2006; 281:12699-704.
39. Apostolopoulos V, Yu M, Corper AL et al. Crystal structure of a noncanonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J Mol Biol 2002; 318:1307-16.
40. Apostolopoulos V, Chelvanayagam G, Xing PX et al. Anti-MUCl antibodies react directly with MUCl peptides presented by class I H2 and HLA molecules. J Immunol 1998; 161:767-75.
41. Chelvanayagam G, Apostolopoulos V, McKenzie IF. Milestones in the molecular structure of the major histocompatibility complex. Protein Eng 1997; 10:471-4.
42. Meijcrs R, Lai CC, Yang Y et al. Crystal structures of murine MHC Class I H-2 D(b) and K(b) molecules in complex with CTL epitopes from influenza A virus: Implications for TCR repertoire selection and immunodominance. J Mol Biol 2005; 345:1099-110.
43. Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997; 9:89-96.
44. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997; 15:821-50.
45. Kropshofer H, Hammerling GJ, Vogt AB. How HLA-DM edits the MHC class II peptide repertoire: Survival of the fittest? Immunol Today 1997; 18:77-82.
46. Brown JH, Jardetzky TS, Gorga JC et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DRl. Nature 1993; 364:33-9.
47. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DRl complexed with an influenza virus peptide. Nature 1994; 368:215-21.
48. Dessen A, Lawrence CM, Cupo S et al. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7:473-81.
49. Ghosh P, Amaya M, Mellins E et al. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995; 378:457-62.
50. Fremont DH, Hendrickson WA, Marrack P et al. Structures of an MHC class II molecule with covalently bound single peptides. Science 1996; 272:1001-4.
51. Scott CA, Peterson PA, Teyton L et al. Crystal structures of two I-Ad-peptide complexes reveal that high aflSnity can be achieved without large anchor residues. Immunity 1998; 8:319-29.
52. Melvold RW, Wang K, Kohn HI. Histocompatibility gene mutation rates in the mouse: A 25-year review. Immunogenetics 1997; 47:44-54.
53. Luz JG, Huang M, Garcia KC et al. Structural comparison of allogeneic and syngeneic T-cell receptor- peptide-major histocompatibility complex complexes: A buried alloreactive mutation subtly alters peptide presentation substantially increasing V(beta) Interactions. J Exp Med 2002; 195:1175-86.
54. Rodgers JR, Cook RG. MHC class lb molecules bridge innate and acquired immunity. Nat Rev Immunol 2005; 5:459-71.
55. Borrcgo F, Ulbrecht M, Weiss EH et al. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998; 187:813-8.
56. Brand VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391:795-9.
57. Pietra G, Romagnani C, Mazzarino P et al. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T-lymphocytes. Proc Natl Acad Sci USA 2003; 100:10896-901.
58. Allan DS, Colonna M, Lanier LL et al. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med 1999; 189:1149-56.
59. Mallet V, Blaschitz A, Crisa L et al. HLA-G in the human thymus: A subpopulation of medullary epithelial but not CD83(+) dendritic cells expresses HLA-G as a membrane-bound and soluble protein. Int Immunol 1999; 11:889-98.
60. Ishitani A, Sageshima N, Lee N et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F and G in maternal-placental immune recognition. J Immunol 2003; 171:1376-84.
61. Chiang EY, Stroynowski I. A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor. J Immimol 2004; 173:4394-401.
62. Sullivan LC, Hoare HL, McCluskey J et al. A structural perspective on MHC class lb molecules in adaptive immunity. Trends Immunol 2006.
63. Clements CS, Kjer-Nielsen L, Kostenko L et al. Crystal structure of HLA-G: A nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA 2005; 102:3360-5.
64. Joyce S, Tabaczewski P, Angeletti RH et al. A nonpolymorphic major histocompatibility complex class lb molecule binds a large array of diverse self-peptides. J Exp Med 1994; 179:579-88.
65. He X, Tabaczewski P, Ho J et al. Promiscuous antigen presentation by the nonclassical MHC lb Qa-2 is enabled by a shallow, hydrophobic groove and self-stabilized peptide conformation. Structure 2001; 9:1213-24.
66. Wang CR, Castano AR, Peterson PA et al. Nonclassical binding of formylated peptide in crystal structure of the MHC class lb molecule H2-M3. Cell 1995; 82:655-64.
67. Lebron JA, Bennett MJ, Vaughn DE et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93:111-23.
68. Alfonso C, Karlsson L. Nonclassical MHC class II molecules. Annu Rev Immunol 2000; 18:113-42.
69. Garboczi DN, Ghosh P, Utz U et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996; 384:134-41.
70. Garcia KC, Degano M, Stanfield RL et al. An alphabeta T-cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996; 274:209-19.
71. Garcia KC, Degano M, Pease LR et al. Structural basis of plasticity in T-cell receptor recognition of a self peptide-MHC antigen. Science 1998; 279:1166-72.
72. Reinherz EL, Tan K, Tang L et al. I h e crystal structure of a T-cell receptor in complex with peptide and MHC class II. Science 1999; 286:1913-21.
73. Hoare HL, Sullivan LC, Pietra G et al. Structural basis for a major histocompatibility complex class lb-restricted T-cell response. Nat Immunol 2006; 7:256-64.
74. Adams EJ, Chien YH, Garcia KC. Structure of a gammadelta T-cell receptor in complex with the nonclassical MHC T22. Science 2005; 308:227-31.
75. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994; 372:379-83.
76. Rudolph MG, Stanfield RL, Wilson lA. How TCRs bind MHCs, peptides and coreceptors. Annu Rev Immunol 2006; 24:419-66.
77. Chatterjee D, Khoo KH. Mycobacterial lipoarabinomannan: An extraordinary lipoheteroglycan with profound physiological effects. Glycobiology 1998; 8:113-20.
78. Zeng Z, Castano AR, Segelke BW et al. Crystal structure of mouse CDl: An MHC-like fold with a large hydrophobic binding groove. Science 1997; 277:339-45.